Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical

Biogen/Elan Tysabri Combination Use Higher Than Expected Since Launch

  • News

Executive Summary

Demand for Biogen Idec/Elan's Tysabri for combination use with other multiple sclerosis therapies has been greater than expected in the product's first two months on the market

You may also be interested in...



Tysabri Return To Market With Expanded Indication Backed By Committee

Biogen Idec's Tysabri could return to market as early as April with an expanded indication following review by FDA's Peripheral & Central Nervous System Drugs Advisory Committee on March 7-8

Tysabri Return To Market With Expanded Indication Backed By Committee

Biogen Idec's Tysabri could return to market as early as April with an expanded indication following review by FDA's Peripheral & Central Nervous System Drugs Advisory Committee on March 7-8

Tysabri Withdrawn Pending Analysis Of Safety Signal In Long-Term Trial

Biogen Idec and Elan are convening a panel of experts on progressive multifocal leukoencephalopathy as the first step towards reintroducing the multiple sclerosis therapy Tysabri (natalizumab)

Table

View full table

Related Content

Pink Sheet

Topics

Tags:
BioPharmaceutical
UsernamePublicRestriction

Register

LL1133546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By